Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XS228 in Subacute Spinal Cord Injury
NCT06976229Phase 1Recruiting
- Start
- Jul 2025
- Primary completion
- Feb 2028
- Modality
- Neural Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XS228 in spinal cord injury (SCI). Primary endpoints: Incidence of adverse events (AEs) and serious adverse events (SAEs), Dose-limiting toxicity (DLT) and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
XS228
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT06976229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976229.